Mangoceuticals, Inc.
Mangoceuticals, Inc. is listed today as Mangoceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2022 | $2 M | No. 1 | Under $2 million | equity, options | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Mangoceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2022).
SEC Form D · Oct 2022
The industry group it chose in its notices: Other.
SEC Form D · Oct 2022
Products and services#
No products or services of Mangoceuticals, Inc. are on record.
Investors#
No investor of Mangoceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Largest shareholders today
Institutions holding Mangoceuticals, Inc. shares, as of Sep 30, 2026.
- Geode Capital Management, LLC$0 M3.20%
- Jane Street Group, LLC$0 M1.00%
- Citadel Advisors LLC$0 M0.88%
- Ikarian Capital, LLC$0 M0.64%
- Vanguard Capital Management LLC$0 M0.57%
- Morgan Stanley$0 M0.33%
- Vanguard Fiduciary Trust Co$0 M0.27%
- Boothbay Fund Management, LLC$0 M0.18%
- Northern Trust Corp$0 M0.17%
- Ackerman Capital Advisors, LLC$0 M0.16%
- StoneX Group Inc.$0 M0.11%
- XTX Topco Ltd$0 M0.10%
- ACT Advisors, LLC.$0 M0.06%
- Csenge Advisory Group$0 M0.05%
- Fortitude Family Office, LLC$0 M0.01%
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jacob Cohen | Executive officer | Oct 2022 |
| Jonathan Arango | Executive officer | Oct 2022 |
| Jacob Cohen | Director | Oct 2022 |
| Jonathan Arango | Director | Oct 2022 |
Went public since 2023. Its SEC number is that of a company listed on a stock exchange.